Press release
Bile Duct Cancer (Cholangiocarcinoma) Pipeline Report 2024 | Clinical Trials, FDA, EMA, PMDA Approvals, Drugs, and Companies
Explore our latest breakthroughs in Bile Duct Cancer (Cholangiocarcinoma) Research. Learn more about our innovative pipeline today! @ Bile Duct Cancer (Cholangiocarcinoma) Pipeline Outlook [https://www.delveinsight.com/sample-request/bile-duct-cancer-cholangiocarcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Bile Duct Cancer (Cholangiocarcinoma) Pipeline Report
* June 2024:- TransThera Sciences (Nanjing) Inc .- This study is a Phase III, Randomized, Controlled, Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician's Choice in Subjects with Fibroblast Growth Factor Receptor (FGFR)-altered, Chemotherapy- and FGFR Inhibitor-Refractory/Relapsed Cholangiocarcinoma.
* June 2024:- Australasian Gastro-Intestinal Trials Group- The aim of this study is to investigate whether the combination of durvalumab and olaparib in the maintenance setting after initial chemotherapy and durvalumab will benefit patients with locally advanced or metastatic cholangiocarcinoma.
* June 2024:- Ze-yang Ding, MD - This is an open-label, single-arm, phase 2 study. The purpose of study is to evaluate the feasibility and safety of hepatic artery infusion chemotherapy combined with lenvatinib and pucotenlimab as conversion therapy for unresectable intrahepatic cholangiocarcinoma.
* June 2024:- M.D. Anderson Cancer Center - Phase II Trial of Pemigatinib in Combination With Atezolizumab and Bevacizumab for Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion. To learn if pemigatinib in combination with atezolizumab and bevacizumab can help to control cholangiocarcinoma.
* June 2024:- Institut fur Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest - The present clinical trial is a prospective, investigator-initiated, single-arm, open-label, multicenter phase II trial. Patients with unresectable perihilar and/or ductal CCA with indication for bile duct stenting and palliative systemic therapy as determined by the local multidisciplinary team (MDT), who already resolved cholestasis due to RFA + Stent will be enrolled.
* DelveInsight's Bile Duct Cancer (Cholangiocarcinoma) pipeline report depicts a robust space with 50+ active players working to develop 60+ pipeline therapies for Bile Duct Cancer (Cholangiocarcinoma) treatment.
* The leading Bile Duct Cancer (Cholangiocarcinoma) Companies such as Wellmarker Bio, Virogin Biotech Canada, TransThera Sciences, Tango Therapeutics, Taiho Oncology, Tyra Biosciences, Anheart Therapeutics, Nuvalent, Array BioPharma, InnoCare Pharma, NextPoint Therapeutics , and others.
* Promising Bile Duct Cancer (Cholangiocarcinoma) Therapies such as GNS561 + Trametinib, Tinengotinib 8 mg, Durvalumab, E7090, Pemigatinib, Gemcitabine, Cisplatin, Ivosidenib , and others.
Stay informed about the cutting-edge advancements in Bile Duct Cancer (Cholangiocarcinoma) treatments. Download for updates and be a part of the revolution in cancer care @ Bile Duct Cancer (Cholangiocarcinoma) Clinical Trials Assessment [https://www.delveinsight.com/sample-request/bile-duct-cancer-cholangiocarcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Bile Duct Cancer (Cholangiocarcinoma) Emerging Drugs Profile
* TT-00420: TransThera Biosciences
TT-00420 is an innovative, global phase III stage spectrum-selective kinase inhibitor that exerts antitumor effects by targeting tumor cells and improving the tumor microenvironment. Ongoing clinical trials in the US and China have revealed the potential of TT-00420 to be efficacious in various solid tumors. It was granted the Orphan-Drug Designation and Fast Track Designation by the FDA for the treatment of CCA. In July 2023, TT-00420 was granted the Breakthrough Therapy Designation (BTD) by NMPA in China.
* VG161: Virogin Biotech
VG161, Virogin's pioneering oncolytic virus built on the company's proprietary SynerlyticTM Platform, is an attenuated herpes simplex virus type 1 (HSV-1) armed with multiple payloads of IL12 & IL15/IL15Ra and a unique PD-L1 blocking peptide. The neurovirulence of wild-type HSV-1 is mitigated by the deletion of ICP 34.5 gene. These payloads can synergistically stimulate both innate and adaptive anti-tumor immunity in the tumor microenvironment. VG161 has been confirmed to be safe and effective in many tumor xenograft mouse models and in GLP toxicity studies preclinically. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Cholangiocarcinoma.
* NXP800: Nuvectis Pharma
NXP800 is an oral, small molecule, potentially first-in-class GCN2 kinase activator. NXP800 is also being evaluated in an investigator-initiated study conducted in collaboration with the Mayo Clinic for the treatment of cholangiocarcinoma, an indication for which the FDA granted NXP800 Orphan Drug Designation. The NXP800 development program in platinum-resistant, ARID1a-mutated ovarian cancer was granted Fast Track Designation by the FDA. NXP800 completed a Phase 1a dose-escalation study in the first half of 2023. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Cholangiocarcinoma.
Learn more about Bile Duct Cancer (Cholangiocarcinoma) Drugs opportunities in our groundbreaking Bile Duct Cancer (Cholangiocarcinoma) Research and development projects @ Bile Duct Cancer (Cholangiocarcinoma) Unmet Needs [https://www.delveinsight.com/sample-request/bile-duct-cancer-cholangiocarcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Bile Duct Cancer (Cholangiocarcinoma) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration
* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical
Bile Duct Cancer (Cholangiocarcinoma) Products have been categorized under various Molecule types such as
* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy
Discover the latest advancements in Bile Duct Cancer (Cholangiocarcinoma) treatment by visiting our website. Stay informed about how we're transforming the future of oncology @ Bile Duct Cancer (Cholangiocarcinoma) Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/bile-duct-cancer-cholangiocarcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Bile Duct Cancer (Cholangiocarcinoma) Pipeline Report
* Coverage- Global
* Bile Duct Cancer (Cholangiocarcinoma) Companies- Wellmarker Bio, Virogin Biotech Canada, TransThera Sciences, Tango Therapeutics, Taiho Oncology, Tyra Biosciences, Anheart Therapeutics, Nuvalent, Array BioPharma, InnoCare Pharma, NextPoint Therapeutics, and others.
* Bile Duct Cancer (Cholangiocarcinoma) Therapies- GNS561 + Trametinib, Tinengotinib 8 mg, Durvalumab, E7090, Pemigatinib, Gemcitabine, Cisplatin, Ivosidenib, and others.
* Bile Duct Cancer (Cholangiocarcinoma) Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Bile Duct Cancer (Cholangiocarcinoma) Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of Bile Duct Cancer (Cholangiocarcinoma) pipeline on our website @ Bile Duct Cancer (Cholangiocarcinoma) Emerging Drugs and Companies [https://www.delveinsight.com/sample-request/bile-duct-cancer-cholangiocarcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Bile Duct Cancer (Cholangiocarcinoma): Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Bile Duct Cancer (Cholangiocarcinoma)- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* TT-00420: TransThera Biosciences
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* VG161: Virogin Biotech
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* NXP800: Nuvectis Pharma
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug name: Company name
* Drug profiles in the detailed report.....
* Inactive Products
* Bile Duct Cancer (Cholangiocarcinoma) Key Companies
* Bile Duct Cancer (Cholangiocarcinoma) Key Products
* Bile Duct Cancer (Cholangiocarcinoma)- Unmet Needs
* Bile Duct Cancer (Cholangiocarcinoma)- Market Drivers and Barriers
* Bile Duct Cancer (Cholangiocarcinoma)- Future Perspectives and Conclusion
* Bile Duct Cancer (Cholangiocarcinoma) Analyst Views
* Bile Duct Cancer (Cholangiocarcinoma) Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=bile-duct-cancer-cholangiocarcinoma-pipeline-report-2024-clinical-trials-fda-ema-pmda-approvals-drugs-and-companies]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Bile Duct Cancer (Cholangiocarcinoma) Pipeline Report 2024 | Clinical Trials, FDA, EMA, PMDA Approvals, Drugs, and Companies here
News-ID: 3542093 • Views: …
More Releases from ABNewswire
Tampa Bay Remodeling Trends 2025: What Homeowners Are Choosing for Kitchen, Bath …
Tampa Bay's home remodeling trends in 2025 reflect a growing demand for smart kitchens, spa-style bathrooms, energy-efficient upgrades, and multi-generational living solutions. Based on local projects across South Tampa, Clearwater, and Wesley Chapel, this analysis highlights the top renovation features Tampa homeowners are prioritizing, with insights from licensed contractor Dan Blizer of Craftline Remodeling.
Industry Analysis Reveals Shift Toward Sustainable Materials, Smart Home Integration, and Multi-Generational Design Solutions
Tampa Bay's home remodeling…
Durable, Precise, Powerful: Meet HUDEF's Apex Pro2 Pickleball Paddle
Many pickleball players face issues with paddles that lose shape or fail to provide consistent control after repeated use. Traditional foam and EPP cores, while lightweight, often deform, negatively impacting accuracy and performance. The HUDEF Apex Pro2 Pickleball Paddle addresses these problems with its innovative Supercritical Foaming Polypropylene Honeycomb Core, ensuring durability and improved performance during gameplay.
New York - Sep 10, 2025 - Many pickleball players struggle with paddles that…
Morristown, NJ Homeowners Trust Freedom Plumbing for Affordable Water Heater Rep …
Freedom Plumbing is the trusted choice in Morristown, NJ for affordable water heater repairs and installations, keeping homes comfortable and reliable year-round.
Morristown, NJ - For many households, hot water is essential to daily life, from morning showers to evening chores. When water heaters fail or show signs of wear, the disruption can be significant. In Morristown, residents are increasingly turning to professional plumbing services to ensure their systems are running…
What to Do During a Plumbing Emergency: Joe Castro Plumbing Provides Crucial Tip …
Joe Castro Plumbing shares essential tips for Oak Ridge North residents on handling plumbing emergencies safely until professional help arrives.
Oak Ridge North, TX - Plumbing emergencies can happen without warning, and when they do, fast action is essential to minimize damage and restore safety. From burst pipes to overflowing toilets, these unexpected situations can disrupt daily life and cause costly repairs if not handled promptly. Local residents are being reminded…
More Releases for Cholangiocarcinoma
Cholangiocarcinoma Market to Reach USD 2.87 Billion by 2034
The global cholangiocarcinoma market is positioned for steady growth, driven by increasing awareness, improved diagnostic capabilities, and the expanding approval of targeted drugs. Between 2024 and 2034, a combination of innovative drug pipelines, biomarker-based diagnostics, and supportive policy frameworks is expected to transform patient outcomes.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/70843
Market Overview
• Market Size (2024): USD 1.32 billion
• Forecasted Market Size (2034): USD 2.87 billion
• CAGR (2024-2034): ~8.1%
• Key Drivers: Genomic…
Cholangiocarcinoma Pipeline Outlook Report 2024 (Updated)
DelveInsight's, "Cholangiocarcinoma Pipeline Insight 2024" report provides comprehensive insights about 55+ companies and 60+ pipeline drugs in Cholangiocarcinoma pipeline landscape. It covers the Cholangiocarcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Cholangiocarcinoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Cholangiocarcinoma Pipeline Report
• DelveInsight's Cholangiocarcinoma pipeline…
Cholangiocarcinoma Market Size was USD 786.1 million in 2021
The Cholangiocarcinoma Market is expected to show positive growth attributed to the increased diagnosed prevalence and also, the launch of upcoming devices during the forecast period. Moreover, advances in disease mechanisms have yielded new diagnostic and treatment approaches, opening avenues to better treatment interventions.
The Cholangiocarcinoma market report provides current treatment practices, emerging drugs, Cholangiocarcinoma market share of the individual therapies, current and forecasted Cholangiocarcinoma market Size from 2019 to 2032…
Global Cholangiocarcinoma Market
The global cholangiocarcinoma market size was valued at USD 185 million in 2021 and is projected to reach around USD 450 million in 2030 exhibiting a CAGR of 12.5% in the forecasted period. The high expenditure on the healthcare sector by the management and the customers boosts the market growth. Increasing infection like liver fluke will boost the demand for the market, growing the treatment of bile duct cancer impacting…
Cholangiocarcinoma Market Overview by Advance Technology, Future Outlook 2032
The global cholangiocarcinoma market size was valued at USD 185 million in 2021 and is projected to reach around USD 450 million in 2030 exhibiting a CAGR of 12.5% in the forecasted period. The high expenditure on the healthcare sector by the management and the customers boosts the market growth. Increasing infection like liver fluke will boost the demand for the market, growing the treatment of bile duct cancer impacting…
Cholangiocarcinoma Market Size was USD 786.1 Million in 2021
"The increase in Cholangiocarcinoma market size is a direct consequence of increasing incident population of Cholangiocarcinoma, an increase in investment in the R&D of drugs leading to a rich pipeline in the 7MM"
The Cholangiocarcinoma market report provides current treatment practices, emerging drugs, cholangiocarcinoma market share of the individual therapies, current and forecasted cholangiocarcinoma market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current cholangiocarcinoma…
